FIRAZYR
Total Payments
$4.5M
Transactions
2,371
Doctors
1,046
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $340,606 | 19 | 1 |
| 2022 | $1,825 | 3 | 3 |
| 2021 | $1.4M | 54 | 1 |
| 2020 | $731,121 | 15 | 8 |
| 2019 | $1.2M | 19 | 15 |
| 2018 | $122,800 | 1,088 | 656 |
| 2017 | $742,553 | 1,173 | 645 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 104 | 97.7% |
| Consulting Fee | $46,300 | 14 | 1.0% |
| Food and Beverage | $37,001 | 2,209 | 0.8% |
| Travel and Lodging | $9,672 | 33 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,563 | 8 | 0.2% |
| Education | $39.13 | 3 | 0.0% |
Payments by Type
Research
$4.4M
104 transactions
General
$102,576
2,267 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MECHANISMS UNDERLYING CARDIOVASCULAR EFFECTS OF ARBNEP INHIBITION AIM 2 | Shire North American Group Inc | $1.4M | 0 |
| MECHANISM(S) UNDERLYING CARDIOVASCULAR EFFECTS OF ARB/NEP INHIBITION ? AIM 2 | Takeda Pharmaceuticals U.S.A., Inc. | $947,586 | 0 |
| DISCOVERING POTENTIAL PERIPHERAL BLOOD BIOMARKERS FOR DIAGNOSIS AND MANAGEMENT OF HEREDITARY ANGIOEDEMA ATTACKS | Shire North American Group Inc | $163,265 | 0 |
| Discovering potential peripheral blood biomarkers for diagnosis and management of Hereditary Angioedema attacks | Shire North American Group Inc | $128,086 | 0 |
| BIOMARKERS FORTYPE III HEREDITARY ANGIOEDEMA | Shire North American Group Inc | $85,755 | 0 |
| BIOMARKERS FORTYPE III HEREDITARY ANGIOEDEMA | Takeda Pharmaceuticals U.S.A., Inc. | $42,877 | 0 |
| EFFECT OF BRADYKININ RECEPTOR ANTAGONISM ON ACE INHIBITOR ASSOCIATED ANGIODEMA - A MULTICENTER TRIAL | Shire North American Group Inc | $42,072 | 0 |
| MITOCHONDRIAL DYSFUNCTION IN CHRONIC KIDNEY DISEASE ADOLESCENTS WITH HEREDITARY ANGIOEDEMA | Shire North American Group Inc | $28,861 | 0 |
| A MULTICENTER, OPEN-LABEL, NON RANDOMIZED STUDY TO ASSESS THE TOLERABILITY AND SAFETY OF A SINGLE, SUBCUTANEOUS ADMINISTRATION OF ECALLANTIDE IN CHILDREN AND ADOLESCENTS WITH HEREDITARY ANGIOEDEMA | Shire North American Group Inc | $27,688 | 0 |
| PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL STUDY EVALUATING THE SAFETY & EFFICACY OF ICATIBANT AS A TREATMENT FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITOR ACE-I-INDUCED ANGIOEDEMA IN ADULTS | Shire North American Group Inc | $26,168 | 0 |
| PREKALLIKREIN ACTIVATION IN THE ABSENCE OF FACTOR XIIA IN HEREDITARY ANGIOEDEMA | Shire North American Group Inc | $23,332 | 0 |
| PREKALLIKREIN ACTIVATION IN THE ABSENCE OF FACTOR XIIA IN HEREDITARY ANGIOEDEMA | Takeda Pharmaceuticals U.S.A., Inc. | $23,332 | 0 |
| Biomarkers forType III Hereditary Angioedema | Takeda Pharmaceuticals U.S.A., Inc. | $19,877 | 0 |
| EFFECT OF ESTROGEN ON BRADYKININ IN HAE PATIENTS | Takeda Pharmaceuticals U.S.A., Inc. | $15,068 | 0 |
| A MULTICENTER, OPEN-LABEL, NON-RANDOMIZED STUDY TO ASSESS THE PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF A SINGLE SUBCUTANEOUS ADMINISTRATION OF ICATIBANT IN CHILDREN AND ADOLESCENTS WITH HEREDITARY ANGIOEDEMA | Shire North American Group Inc | $7,166 | 1 |
Top Doctors Receiving Payments for FIRAZYR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Flushing, NY | $4.4M | 104 |
| , M.D | Specialist | Dallas, TX | $17,078 | 19 |
| , M.D | Pediatrics | Raleigh, NC | $12,025 | 3 |
| , MD | Allergy & Immunology | Walnut Creek, CA | $9,456 | 13 |
| , M.D | Internal Medicine | Layton, UT | $6,478 | 9 |
| , MD | Allergy & Immunology | Scottsdale, AZ | $6,241 | 15 |
| , M.D | Pediatric Allergy/Immunology | Santa Monica, CA | $6,084 | 16 |
| , M.D | Student in an Organized Health Care Education/Training Program | Homewood, AL | $5,401 | 8 |
| , MD | Allergy & Immunology | Washington, DC | $3,261 | 8 |
| , MD | Clinical & Laboratory Immunology | Boston, MA | $2,250 | 1 |
| , MD | Allergy & Immunology | San Diego, CA | $1,800 | 1 |
| , MD | Internal Medicine | Cincinnati, OH | $1,375 | 1 |
| , MD | Internal Medicine | Murray, UT | $1,375 | 1 |
| , DO | Allergy & Immunology | Charlotte, NC | $1,357 | 11 |
| , M.D.; PHD | Allergy & Immunology | Vancouver, WA | $215.18 | 11 |
| , M.D | Specialist | San Francisco, CA | $210.82 | 10 |
| , M.D | Allergy & Immunology | Overland Park, KS | $210.41 | 18 |
| , M.D | Allergy & Immunology | Fresno, CA | $185.05 | 9 |
| , MD | Allergy & Immunology | Plantation, FL | $162.95 | 10 |
| , MD, PHD | Allergy | Wheaton, MD | $160.65 | 8 |
| Lee Sonin | Allergy | Schaumburg, IL | $160.64 | 9 |
| , M.D | Allergy & Immunology | Reading, PA | $158.55 | 9 |
| , M.D | Allergy & Immunology | Pensacola, FL | $151.88 | 10 |
| , M.D | Allergy & Immunology | Roseville, CA | $144.99 | 7 |
| , M.D | Allergy & Immunology | Roseville, CA | $142.63 | 8 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.5M
- Total Doctors 1,046
- Transactions 2,371
About FIRAZYR
FIRAZYR is a drug associated with $4.5M in payments to 1,046 healthcare providers, recorded across 2,371 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2023. In 2023, $340,606 was paid across 19 transactions to 1 doctors.
The most common payment nature for FIRAZYR is "Unspecified" ($4.4M, 97.7% of total).
FIRAZYR is associated with 15 research studies, including "MECHANISMS UNDERLYING CARDIOVASCULAR EFFECTS OF ARBNEP INHIBITION AIM 2" ($1.4M).